03 April 2019 VACCIBODY’S APPROACH TO COST-EFFECTIVE PERSONALIZED CANCER NEOANTIGEN VACCINES INDUCING A UNIQUE CD8-DOMINATED T CELL RESPONSE | Boston, August 2018 Download Go back
